Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China.
Chin Med J (Engl)Aug 24, 2026 (epub)
Yuxiong Jiang, Zhuolin Guo, Lingling Yao et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter prospective cohort study investigated the relationship between serum uric acid (SUA) levels and treatment response to ixekizumab in 390 patients with moderate-to-severe psoriasis in China. Results indicated that patients with hyperuricemia had a lower likelihood of achieving PASI 75 (aOR 0.84), PASI 90 (aOR 0.37), and PASI 100 (aOR 0.57) after 12 weeks of treatment, suggesting SUA may impact treatment efficacy.
Key findings
- Patients with hyperuricemia had a lower likelihood of achieving PASI 75 (aOR 0.84).
- The likelihood of achieving PASI 90 was significantly lower in hyperuricemic patients (aOR 0.37).
- PASI 100 achievement was also less likely in patients with hyperuricemia (aOR 0.57).
- SUA levels correlated with 26 circulating inflammatory proteins.
Why it matters
Understanding the impact of serum uric acid on treatment response in psoriasis can help clinicians tailor management strategies and consider metabolic factors that may influence therapeutic outcomes.